CTLA4 and neoplasm: The combination of immune checkpoint inhibitors, specifically anti-CTLA-4 and anti-PD-1 antibodies, is now providing an effective therapeutic strategy in many cancers, including advanced melanoma, for which tumor regression and long-term durable cancer control is possible in nearly 50% of patients (143, 144).